|
|
Sonela |
|
Cavicke |
|
Vice President of Discovery Business Development |
Sai Life Sciences Ltd |
https://proventainternational.com/wp-content/uploads/2022/03/Sonela-Cavicke-1.jpg |
Since 2020, Sonela Cavicke is the West Coast VP of Business Development for Discovery Services at Sai Life Sciences. Sonela’s research background is in Immunology, particularly immunoassay development for vaccines, biologicals, and biomarkers. She completed her Bachelor’s and Master’s Degrees in Immunology and Microbiology at the University of Texas in Austin. She is a co-founder of a life sciences and diagnostic instrument company, Charted Scientific. She has held R&D positions at Luminex, Life Technologies, Merck Research Laboratories and Amgen and has worked in business development roles at MilliporeSigma, DiscoverX, and Eurofins Discovery prior to joining Sai. |
|
|
Takako |
|
Yoshida-Moriguchi |
|
Drug Discovery Scientist and Program Lead |
Sai Life Sciences |
https://proventainternational.com/wp-content/uploads/2022/03/Takako-Moriguchi-1.jpg |
Takako Yoshida-Moriguchi is an established scientist and program leader in the area of rare disease drug discovery science. She was Group Head of Rare Neuromuscular diseases group at Sanofi Genzyme Drug discovery department, and now leads the Biology group at Sai Life Sciences Exploratory Biology Facilities in Boston. She has pursued Drug discovery research to treat rare and metabolic diseases by utilizing various modalities including small molecule, antisense oligonucleotide, gRNA, bispecific antibodies, and AAV in global pharma and startup settings. |
|
|
Hicham |
|
Alaoui |
|
Chief Scientific Officer |
Glycomine Inc. |
https://proventainternational.com/wp-content/uploads/2021/10/Hicham-Alaoui-scaled-e1641469267704.jpg |
Dr. Alaoui has more than 20 years of experience in a variety of drug discovery and development organizations. Most recently Dr. Alaoui served as Vice President of Biology at Ardelyx where he led a multidisciplinary Research organization consisting of Molecular and Cellular Pharmacology, In vivo Pharmacology and DMPK. Prior to Ardelyx, Dr. Alaoui was the Vice President of Biotherapeutics Research and Development at Codexis and before that Senior Vice President Discovery Biology and co- head of Research at Symic Bio. In these senior leadership roles, Dr. Alaoui was responsible for expanding that company’s pipeline and strategically extending into new therapeutic areas. Dr Alaoui spent several years at Genentech as Director Biochemical and Cellular Pharmacology, ultimately leading a large in vitro pharmacology group dedicated to lead drug discovery and optimization for both biotherapeutic and small molecule programs. Prior to Genentech, he acted as key contributor for driving multiple protein therapeutic candidates into clinical trials, as well as the establishment of novel in vitro and in vivo pharmacology assays through his various R&D leadership positions at Stryker Biotech, VisEn Medical, Neogenesis Pharmaceuticals, and Shire BioChem. Dr. Alaoui earned a Ph.D. in Microbiology and Immunology at McGill University, Montreal, Quebec, Canada, as well as an M.Sc. in Biochemistry from Pierre & Marie Curie Université, Paris, France. Dr. Alaoui has authored numerous peer-reviewed publications, in addition to being named as an inventor on multiple patent applications. |
|
|
Venita |
|
De Almeida |
|
Vice President, Preclinical Development |
3T Biosciences |
https://proventainternational.com/wp-content/uploads/2021/12/Venita-De-Almeida.jpg |
Dr. Venita De Almeida is the Vice President of Program Development at 3T Biosciences in South San Francisco, CA. Venita started her career with her Ph.D. at Northwestern University, where she conducted structure function studies on the GHRH receptor. Venita then did her postdoctoral fellowship at Genentech and was instrumental in demonstrating the anti-tumor activity of multiple biologics that inhibited the Wnt signaling pathway. She continued research in the Oncology department at Genentech, where worked on multiple ADC programs from target validation to identification of development candidates. In 2013, Venita joined Sutro Biopharma and was responsible for setting up preclinical development and led several development programs including the lead clinical program, STRO-002. Venita joined 3T Biosciences in August 2021 where she leads program development.
During her career, Venita has worked on several biologics including fusion proteins, antibodies, ADCs, and bispecifics; and has been involved in numerous INDs and clinical programs. |
|
|
Russell |
|
Bainer |
|
Head, Computational Biology |
Maze Therapeutics |
https://proventainternational.com/wp-content/uploads/2021/10/Russell-Bainer.jpg |
Russell Bainer, Ph.D Leads the Computational Biology group at Maze Therapeutics, a company focused on using integrative human genetic and functional genomics methods to develop therapies for genetic diseases. At Maze, his group plays important roles in diverse experimental, analytical, and methodological efforts to develop and extend experimental biology and drug discovery applications. Dr. Bainer’s research is broadly focused on methodological innovation in functional genomics experiments, with a particular focus on epigenetic technologies and pooled screening applications. |
|
|
Tove |
|
Tuntland |
|
Global Head, DMPK |
Ferring Pharmaceuticals |
https://proventainternational.com/wp-content/uploads/2021/12/Tove-Tuntland-v1.jpg |
Tove Tuntland, Ph.D., heads the Global Drug Metabolism and Pharmacokinetics (DMPK) department at Ferring Pharmaceuticals. Tove joined Ferring in 2021 to oversee a global group that supports preclinical bioanalytical-, ADME-, DMPK- and PK/PD studies in Reproductive Medicine & Maternal Health. She began her career at Pfizer in La Jolla, CA, where she worked for 6 years in discovery and development of antiviral drugs. In 2002 she moved to Novartis Pharmaceuticals in San Diego to build a DMPK group that supported programs in oncology, immunology, infectious and metabolic diseases. Over the next 17 years, the DMPK group at Novartis contributed to the selection of 12 drug candidates into the clinical pipeline, including three marketed oncology drugs (Zykadia®, Odomzo®, Brafttovi®) and one marketed Multiple Sclerosis agent (Mayzent®).
|
|
|
Ryan |
|
Potts |
|
Executive Director and Head, Induced Proximity Platform |
Amgen |
https://proventainternational.com/wp-content/uploads/2021/12/Ryan-Potts.jpg |
Ryan Potts, Ph.D. obtained his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center and was appointed as Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry in 2011. In 2016 his lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. In 2020 he moved to Amgen, Inc. as Executive Director of Research and Head of the Induced Proximity Platform that is focused on drugging the “undruggable”. |
|
|
Werner |
|
Rubas |
|
Vice President, Preclinical Development |
Sutro Biopharma, Inc. |
https://proventainternational.com/wp-content/uploads/2021/02/Werner-Rubas-4.jpg |
Werner Rubas, Ph.D. brings to Sutro 30 years of biotech and pharmaceutical industry experience. Formerly, Dr. Rubas was at Nektar Therapeutics for over nine years, most recently as Executive Director in Non-Clinical Pharmacokinetics and Pharmacodynamics. At Nektar, he provided leadership support, directed the generation of data packages for regulatory submissions of NKTR-214, NKTR-358, NKTR-262, and NKTR-255, filed a patent application for an immunotherapeutic tumor treatment method, and provided scientific input on cross-functional teams from research concepts to late-stage development. Prior to Nektar, Dr. Werner was at Roche in Palo Alto, where he was the Associate Director of the Drug Metabolism and Pharmacokinetics group. Additionally, he has been a SPARK advisor at Stanford University since 2010 and lectures classes on Drug Development at UC Berkeley Extension. Dr. Rubas earned his Ph.D. from ETH, Zurich, and received his pharmacy license from the School of Pharmacy at ETH, Zurich. |
|
|
David |
|
Zarling |
|
Chief Executive Officer |
Colby Pharmaceuticals |
https://proventainternational.com/wp-content/uploads/2021/09/David-Zarling.jpg |
David Alan Zarling, MA Ph.D. MBA is a Co-Founder and CEO of Colby Pharmaceutical Company and leads teams in clinical development of Intra-Nasal, -Lymphatic, -Venous Diagnostics, and companion Immune Modulating anti-viral and anti-cancer immunotherapeutics. David successfully managed Colby teams in asset sales of anti-inflammatory and anti-cancer drugs and in Colby’s subsequent merger acquisition of Othera Pharmaceuticals’ anti-viral, anti-inflammatory, anti-cancer clinical small molecule pharmaceutical drug portfolios. David also successfully completed the worldwide exclusive license from MannKind Corporation to their entire portfolio of infectious, neoplastic, autoimmune, and allergic disease immuno-therapeutic and -diagnostic clinical products. |
The Westin St. Francis San Francisco on Union Square
Payment Securely powered by stripe
